A humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Leukemias represent a significant global health burden, affecting both children and adults and often leading to aggressive, life‑threatening disease. Acute lymphoblastic leukemia (ALL) is among the most common forms and remains challenging to treat despite available therapies. Existing asparaginase drugs play a central role in ALL treatment but are limited by high rates of toxicity and hypersensitivity, which prevent many patients from completing therapy. Safer and more tolerable asparaginase options are needed to expand effective treatment access and improve clinical outcomes.
Emory researchers have developed a humanized therapeutic L asparaginase candidate designed to support the treatment of acute lymphoblastic leukemia (ALL) and other cancers. The approach leverages computational ancestral sequence reconstruction (ASR) to guide the development of L asparaginase variants inspired by sequences found in guinea pig serum. These variants share substantially higher sequence similarity to the human enzyme than currently used bacterial L asparaginases, which may translate to reduced immunogenicity and improved tolerability. Preliminary research indicates that these humanized derivatives have the potential to maintain therapeutic activity while mitigating many of the dose limiting toxicities and hypersensitivity reactions associated with existing asparaginase formulations. This platform-based strategy offers a path toward safer, more effective asparaginase therapies for leukemia and potentially other cancers that rely on asparagine depletion.
Data is now available for in vitro anti-tumor cytotoxicity studies against multiple tumor types as well as immunogenicity in comparison to existing competing technologies.